The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Published:2018-11-28 Issue:12 Volume:17 Page:854-855
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Tang Jun,Yu Jia Xin,Hubbard-Lucey Vanessa M.,Neftelinov Svetoslav T.,Hodge Jeffrey P.,Lin Yunqing

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd.2018.210.pdf

Reference2 articles.

1. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The advancements and prospective developments in anti-tumor targeted therapy;Neoplasia;2024-10

2. Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment;Biomedicine & Pharmacotherapy;2024-10

3. A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy;Molecular Therapy: Oncology;2024-09

4. The basic biology of NK cells and its application in tumor immunotherapy;Frontiers in Immunology;2024-08-16

5. The impact of histone lactylation on the tumor microenvironment and metabolic pathways and its potential in cancer therapy;Genes & Genomics;2024-08-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP